Oculis (NASDAQ:OCS) Sets New 12-Month High – Here’s Why

Shares of Oculis Holding AG (NASDAQ:OCS) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $29.36 and last traded at $29.03, with a volume of 293170 shares traded. The stock had previously closed at $28.45.

Analyst Ratings Changes

OCS has been the subject of several recent analyst reports. Chardan Capital restated a “buy” rating and set a $51.00 target price on shares of Oculis in a research report on Tuesday, November 11th. Bank of America decreased their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. JPMorgan Chase & Co. started coverage on shares of Oculis in a research report on Friday, December 19th. They set an “overweight” rating and a $38.00 target price for the company. HC Wainwright boosted their price target on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.50.

Oculis Price Performance

The stock has a market capitalization of $1.52 billion, a PE ratio of -11.52 and a beta of 0.27. The firm’s 50 day simple moving average is $22.12 and its 200 day simple moving average is $19.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, equities analysts forecast that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently bought and sold shares of OCS. Gildi lifeyrissjodur bought a new position in Oculis during the 4th quarter worth approximately $50,250,000. Aberdeen Group plc increased its stake in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares during the period. Syquant Capital Sas purchased a new stake in Oculis during the 4th quarter valued at $3,849,000. Woodline Partners LP grew its holdings in Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Oculis in the second quarter valued at about $393,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.